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Abstract 
Streptomyces pactum produces an enzyme that converts Arteannuin B to Artemisinin that is an important antimalarial. The 
gene encoding this novel enzyme from Streptomyces pactum MTCC 3664 has been cloned and expressed in Escherichia coli 
BL21 (DE3). The enzyme is expressed in the form of inclusion bodies at 370C or in a soluble form at 280C. The recombinant 
enzyme was purified by Immobilized Metal Ion Affinity Chromatography (IMAC). The purified enzyme produced by constitutive 
expression was found to be functionally active as it showed the conversion of arteannuin B to artemisinin as detected by TLC 
and HPLC.  
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Introduction 
Malaria is the world’s most important parasitic 
infection. Malaria is caused by infection of red blood 
cells with protozoan parasites of genus Plasmodium. In 
humans, the infection is caused by one or more of four 
species of the intracellular protozoan parasite. P. 
falciparum, P. vivax, P. ovale and P. malariae.  The 
most critical problem currently limiting malaria 
treatment is the emergence and spread of parasite 
resistance to the majority of antimalrial drugs in use 
(Woodrow et al., 2005). The frequent failure of the 
conventional treatments using drugs such as 
chloroquine and sulphadoxine-pyrimethamine (Trape, 
2001, Olliaro and Taylor, 2003) have led to the 
emergence of combination therapies (CTs) particularly, 
those formulations containing artemisinin or its 
derivatives (ACTs) as a more reliable treatment option 
(Duffy and Mutabingwa, 2004; Woodrow et al., 2005). 
The use of ACTs in the treatment of malaria has been 
recognized as a long term measure to control spread of 
the disease by the World Health Organization (WHO) 
under its RBM program (WHO, Access to antimalarial 
medicines, 2003). Artemisinin exhibits a quick onset of 
action and high efficacy against the blood stages of 
Plasmodium (ter Kuile et al., 1993). They have also 
been shown to reduce the number and infectivity of 
gametocytes in the blood (Kumar and Zheng, 1990; 
Kombila et al., 1997; Chen et al., 1994 and Targett et 
al., 2001). 
Artemisinin (Fig.1) is a sesquiterpene lactone 
produced from Artemisia annua   Artemisinin was 
isolated in pure form in the year 1972 from Artemisia 
annua (Christen and Veuthey, 2001) and in 1979 its 
structure was elucidated by X-ray analysis (van 
Agtmael, et al., 1999). The structure of this compound 
is rare among secondary plant metabolites in that it 
harbors a peroxide bond in 1,2,4-trioxane heterocycle 
(Avery et al., 1992).  Artemisia annua is the only 
practical source of artemisinin but the concentration of 
artemisinin in A, annua is very low, in the range of 
0.01% – 0.8%. A relatively low yield of artemisinin is a 
serious limitation to the commercialization of the drug 
(Laughlin, 1994). The structure of artemisinin molecule 
is highly complex and the total chemical synthesis of 
artemisinin is uneconomical (Yadav et al., 2003). 
Among the various attempts that have been made to 
enhance the production of artemisinin, 
biotransformation approach has been identified as a 
potential alternative. Arteannuin-B is a biogenetic 
precursor of artemisinin in certain cultivars and is found 
in higher amounts than the end product in Artemisia 
annua   (Nair and Basile, 1993, Singh, 1986 and Akhila 
et al., 1990). Arteannuin-B (Fig. 2) is a sesquiterpene 
with an unusual a-methylene-γ-lactone (Woodrow et al., 
2005). Biotransformation of arteannuin B to artemisinin 
has been carried out with crude leaf homogenates of 
Artemisia annua (Nair and Basile, 1993; Vikas Dhingra, 
et al., 2000). In our laboratory we have adopted the 
microbial biotransformation approach to enhance the 
production of artemisinin, as microorganisms are more 
versatile and easy to handle. We have isolated a 
Streptomyces sp. With the ability to convert arteannuin 
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B to artemisinin by screening various soil samples. The 
enzyme responsible for this bioconversion activity has 
been purified to homogeneity. The purified enzyme has 
shown a 78.8% bioconversion of arteannuin B to 
artemisinin on molar basis. Our studies have shown 
that microbial biotransformation approach is a very 
viable and potential alternative to enhance the 
production of artemisinin.  
 
Fig.1 Artemisinin 
 
 
 
 
 
 
 
 
 
Fig.2 Arteannuin B 
 
 
 
 
 
 
 
 
 The strain, BL21 (DE3), is one of the popular 
strains for the protein expression. BL21 (DE3) contains 
the λDE3 lysogen, which expresses T7 RNA 
polymerase under the control of the lacUV5 promoter1). 
Upon addition of isopropyl-1-thio-β-D-
galactopyranoside (IPTG), T7 RNA polymerase is 
expressed and it induces a high-level protein 
expression from T7 promoter driven expression vectors 
(e.g., pRSET A). E. Coli BL21 (DE3) strain is a 
derivative of E. coli B strain and lacks both the lon 
protease and the ompT membrane protease which 
may degrade expressed proteins (Andreishcheva et al., 
2006). 
The present perspective of the study is to express 
and purification of the enzyme which involved in the 
bioconversion of arteannuin B to Artemisinin. 
Materials and Methods 
Strain and Reagents 
Streptomyces pactum MTCC 3664 strain was 
isolated in our lab and subsequently deposited in 
Microbial type culture collection (MTCC). All Media and 
analytical grade chemicals were purchased from Hi 
media and sigma. 
Purification of the enzyme involved in 
Bioconversion 
Purification of the enzyme involved in 
bioconversion was attempted using different methods 
such as ammonium sulphate precipitation, ion 
exchange chromatography, affinity chromatography 
and gel-filtration chromatography. The fraction of 
proteins precipitating between 0-50% ammonium 
sulfate saturation was further purified by passing 
through Q-sepharose, an anion-exchange column 
using 50mM Tris buffer (pH-7.2). Active fraction eluting 
at 0.3 M Sodium chloride was further purified by gel-
filtration chromatography on Sephacryl-S-100 HR 
column. Proteins were eluted with 50mM Tris-HCl (pH 
7.2) with a flow rate of 12 ml/h. SDS-PAGE (Sodium 
Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis) 
was performed according to Laemmeli (1970), using 
10% polyacrylamide gels in amersham gel 
electrophoresis unit (Amersham Biosciences, 
Minnesota USA). The active fraction obtained from gel-
filtration chromatography was subjected to SDS-PAGE 
analysis. Electrophoresis was carried out at a constant 
voltage of 75 v/cm at room temperature. 
Electrophoresis was carried out until the tracking dye 
reached the end of the gel. Standard medium range 
molecular weight markers (Medium range Genei, 
Bangalore, India) were also electrophoresed along side 
for reference. Comassie brilliant blue R250 staining 
was used to visualize protein bands on the gels 
(Morrissey 1981). The molecular mass of the purified 
enzyme was determined by comparison of its 
electrophoretic mobility with that of marker proteins (Fig. 
3).  
N- Terminal and MALDI TOF analysis of the purified 
enzyme 
The band of interest was transferred from the 
SDS-PAGE gel to PVDF membrane by using Western 
blotting. The protein sample derived from PVDF 
membrane was subjected to chemical modifications 
(reduction and alkylation). The protein sample was 
digested with trypsin. The MALDI probe was inserted 
into the Mass Spectrometer (Bruker & Ultraflex) and 
mass spectrum was acquired using flex controlTM 2.2 
software (Webster, 2005). Peptide mass finger printing 
of the purified enzyme by MALDI-TOF has showed it in 
Fig.4 & 5.  
Design of suitable primers 
The forward primer was designed by using N-
Terminal sequence (MANDAST), it is corresponding to 
nucleotides 1 to 21 and the restriction cleavage sites 
for Xho1 as under lined were included. The reverse 
primer was designed by using MALDI-TOF sequence it 
is complementary to the nucleotides 1258 to 1278 in 
gene. The restriction cleavage sites for Nco1 as shown 
in bold were included in reverse primer.  
5’-ATCGCTCGAGACCGTTTTCGACCTAGTGA-3’ 
5’-ATCGCCATGGCTAGTCGTGGGCGTGCAG-3’ 
The length and melting temperature of the 
oligonucleotide have been kept sufficiently high of 620C  
to avoid any non-specific amplification.  
Jyotheeswara Reddy Eedula et al./Rec Res Sci Tech 3(2011) 90-96 
 
Cloning and expression 
Polymerase Chain Reaction (PCR) 
Preparative PCR was carried out in 500 µl 
reaction (10 × 50 µl) for 25 cycles using Taq DNA 
polymerase and PfuTM DNA polymerase (Stratagene, 
USA, which has 3’-5’ exo nuclease proof reading 
activity) in a ratio of 24:1, in a GeneAmp 9700 thermal 
cycler (Perkin-Elmer Applied Biosystems). The reaction 
was set up as shown in Table 1 and 50 µl of the 
reaction mixture was distributed into ten PCR tubes.
 
Table 1: PCR reaction for amplifying JIC gene 
 
 
 
 
 
 
 
 
 
 
 
The initial denaturation at 940C for 3 min was 
followed by 25 cycles of PCR involving denaturation of 
the template DNA at 940C for 30 sec, annealing of the 
primers to the template DNA at 620C for 40 sec and 
extension of the annealed primer at 720C for 60 sec. 
For final extension the block temperature was kept at 
720C for 10 min. The block was finally allowed to cool 
down at 40C.   
A proof reading thermo stable enzyme Pfu TM DNA 
polymerase was used in association with Taq DNA 
polymerase for PCR, which helped in avoiding any 
misincorporations. The primer could successfully 
amplify the gene as evidenced by agarose gel 
electrophoretic (Sambrook., 2001)  analysis of  PCR 
amplified product  (Fig.7) . 
  
Fig. 6 Genomic DNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lanes 1-3 Lambda DNA (50ng/µl); 
                         Lanes 4-8 Genomic DNA 
 
 
 
Fig. 7  PCR amplification of the desired gene 
 
 
 
 
 
 
 
 
 
 
 
                      
 
 
Lane 1 NEB Ladder (100bp); 
Lanes 2-8 PCR  amplified product 
 
Genomic DNA (Fig.6) from Streptomyces pactum 
was isolated by the improved high salt method and was 
subjected to polymerase chain reaction (PCR) by 
forward and reverse primers based on the N-Terminal 
and MALDI-TOF analysis a set of specific primers were 
designed by using primer 3 software. After purification 
by running 1.2% agarose gel  electrophoresis for 1 h at 
10 V/cm, the PCR amplified product was digested with 
Xho1 and Nco1(Invitrogen) and cloned into pRSET A 
vector (Novagen, Madison, WI) 
The expression plasmid pRSET A- containing the 
gene was transformed into competent E. coli BL21 
(DE3) (Novagen, Madison, WI). Multiple hosts 
containing appropriate construct were first grown on  
LB plates supplemented with 100 mg/ml Ampicillin at 
370C overnight. Several single colonies were seeded 
into 5 ml liquid LB (Ampicillin 100 mg/ml) and cultured 
at 370C overnight. Then the strain expressing the gene 
insert was inoculated (1:100) into 500 ml shake flask 
with 100 ml of LB medium containing 100 mg/ml 
Ampicillin, which was placed on a incubated shaker at 
(180 rpm) at 370C till the OD600 reached 0.6. Later the 
Master mix components Volume in µl for 1 reaction Final volume in µl 
 Template DNA (50 ng) 1.0 10.0 
Forward primer (10 pmoles /µl) 2.0 20.0 
Reverse primer (10 pmoles 
/µl) 
2.0 20.0 
dNTP’s Mix (2 mM) 5.0 50.0 
Pfu Polymerase Buffer 5.0 50.0 
Taq and Pfu Polymerase 
(24:1) 
1.0 10.0 
Distilled water 34.0 340.0 
TOTAL 50.0 500.0 
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cells were induced by 0.5mM and 1.0mM IPTG and 
cells were grown at 37, 30, 28, and 230C. Aliquots of 
the culture were withdrawn at different time intervals 
(1,2,3,4,5,6 and 10 h) and collected by centrifugation. 
The pellets were either prepared immediately for SDS-
PAGE or stored at -800C for the analysis of protein 
expression. 
 
Purification of Recombinant protein 
Cells were harvested from 500 ml LB broth culture 
by centrifugation (8000 rpm, 15 min) and the pelleted 
bacteria were resuspended in 100 ml cold lysis buffer 
(50 mM NaH2PO4, 300 mM Nacl, 10 mM imidazole, pH 
8.0; one tablet of protease inhibitor complete EDTA-
free (Roche);10 µg/ml RNase A (Sigma); 5 µg/ml 
DNase 1 (Sigma),0.1 mg/ml lysozyme (Sigma)). The 
cell lysate was disrupted by sonication on ice for 10 
minutes  with the following parameters i) sonication 
power of 750 watts; ii) pulse duration 9 sec with 5 
seconds gap between pulses and cell debris was 
removed by centrifugation (9000 rpm for 20 min at 40C). 
The soluble lysate supernatant and insoluble cell 
debris were analyzed by SDS-PAGE. 
For purification of the soluble enzyme, an 
Immobilized metal ion affinity chromatography (IMAC) 
purification method was followed. Firstly, the soluble 
lysate supernatant was transformed to a new sterilized 
Falcon tube by filter (0.45 µm) and mixed gently with 5 
ml of Ni-NTA His bind equilibrated with lysis buffer 
(described above) by shaking at 40C for 1 h. then the 
supernatant/resin mixture was located to 
chromatography columns equilibrated with five column 
volumes lysis buffer, allowing bound resin to pack 
under gravity flow. 
The column bed was washed with 10 column 
volumes of wash buffer (50 mM NaH2PO4, 300 mM 
NaCl, 20 mM Imidazole, pH 8.0 using NaOH; one 
tablet of protease inhibitor complete EDTA-free 
(Roche); 10 µg/ml RNase A (Sigma); 5 µg/ml DNase 1 
(Sigma); 0.1 mg.ml lysozyme (Sigma)) to remove 
hybrid proteins. Subsequently, the fusion protein was 
eluted with an imidazole gradient (50-250 mM) in 
elution buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0). 
The eluted protein was analyzed by SDS-PAGE and 
dialyzed against buffer (300 mM NaCl, 50 mM 
NaH2PO4, pH 8.0) to remove imidazole at 40C overnight. 
 
Determination of Protein activity  
Bioconversion Assay: 
Incubation system: The enzyme activity was 
assayed by incubating a mixture of 3 ml of purified JIC 
enzyme with 100 µg of arteannuin B, and the co-
factors: 0.1mM ATP, 1 mM Mg+2 , 1 mM Mn+2  , and 0.1 
mM NADPH in 50 mM Tris-HCL buffer (pH 7.2) for a 
period of 3 h at 300C. Parallel to this, a control was run 
with all other than components except the substrate 
(Nair & Basile, 1993).  
Extraction of artemisinin: On completion of 
incubation time, the reaction was stopped by adding 
ethanol and chloroform in 1:1 proportion. Artemisinin 
was extracted twice from the reaction mixture with 
hexane in a separating funnel. The hexane fraction 
was collected in a separate collection beaker and was 
allowed to evaporate. 
Detection of artemisinin by TLC: The residue 
was dissolved in methanol and was tested for the 
presence of artemisinin by performing thin layer 
chromatography (TLC) on silica gel 60 plates (Merck) 
with a mobile phase of ethyl acetate and hexane in a 
ratio of 2:8. The authentic sample of arteannuin B and 
artemisinin were spotted on TLC plate together with 
control and experiment. The plates were kept in vertical 
position in solvent system in a closed chamber 
saturated with solvent vapors. After allowing the 
solvent system to run about ¾ on the plate, the plate 
was removed and dried. The plate was sprayed with 
iodine vapors for visualization of spots.  
Quantification: Artemisinin produced by 
bioconversion of arteannuin B using crude enzyme of  
E. coli BL21 (DE3) was quantified by HPLC (Gupta et 
al., 1997). HPLC was performed on Shimadzu 
Prominent  series using a Kromasil 100, C 18 column 
(150 X 4.6 mm, ODS with particle size of 5 µm) with a 
mobile phase of 1% (v/v) TFA in water: acetonitrile 
(30:70), at a flow rate of 1 ml/min. Artemisinin was 
monitored at 220 nm with a PDA detector (Shimadzu: 
SPD M20A). The chromatographic system was 
controlled by LC solutions (version 1.2) software. 
Filtered samples of standard artemisinin (Sigma-
Aldrich) (1mg/ml), arteannuin B (0.5mg/ml), and the 
methanolic extract of the experimental sample were 
loaded on to the column. The retention time for 
artemisinin was 6.3 min and that of arteannuin B was 
5.4 min. One unit (U) of enzyme activity was defined as 
the amount enzyme that catalyzed the conversion of 
arteannuin B to artemisinin per min at 300C.  
 
Results 
Purification of the enzyme 
SDS-PAGE (Sodium Dodecyl Sulphate-
Polyacrylamide Gel Electrophoresis) was performed 
according to Laemmeli (1970), using 10% 
polyacrylamide gels in amersham gel electrophoresis 
unit (Amersham Biosciences, Minnesota USA). The 
active fraction obtained from gel-filtration 
chromatography was subjected to SDS-PAGE 
analysis.The purified enzyme shows the molecular 
weight of 38.5 kDa. 
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Fig 3. SDS-PAGE analysis of purified JIC protein involved in 
bioconversion MALDI Characterization 
 
 
 
 
 
 
 
 
 
The amino acid sequence obtained as per MALDI 
TOF analysis revealed that the enzyme under 
consideration is a dioxygenase with 46% sequence 
similarity to the putative dioxygenase subunit alpha 
yeaW protein of Mycobacterium marinum M. As the 
match percentage is less it is presumed to be a hitherto 
unknown protein 
 
Fig 4. MALDI-TOF analysis. The peaks represents the 
fragments generated by Trypsin digestion of JIC protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig 5. Trypsin finger print of JIC protein 
 
 
 
 
 
 
 
 
 
 
 
Expression and purification of JIC enzyme 
encoding gene 
The encoding gene and the pRSET A vector were 
transformed into competent E. coli BL21 (DE3) as 
described in materials and methods section. Based on 
previous publications about protein expression 
(Colleluori et al., 2005 and Xiong et al., 2006), 
preliminary expression experiments of JIC encoding 
gene were done in shake flask with or without IPTG 
induction at 370C. At this temperature, a band 
corresponding to JIC protein with the expected 
molecular weight (Fig.8) was shown for the  expressing 
strain with IPTG induction. However, the majority of 
protein was accumulated in insoluble form, the minority 
in soluble form. Subsequently, by performing the 
expression experiments at 37, 30, 28, and 230C, the 
soluble fraction was remarkably increased (Fig.9), 
especially at 280C, the soluble JIC protein arrived at 
88% of the total cellular protein from a 500 ml culture 
(Fig.10 & 11), which was determined by densitometric 
scanning of SDS-PAGE gels, and the inclusion bodies 
were correspondingly decreased. This suggest that a 
lower temperature is beneficial for expression of JIC 
protein in the form of soluble fraction in E. coli.  
 
Fig.9                                                     Fig.8                                                  
 
 
 
 
 
 
 
 
 
 
                                                         
Fig.8 Lanes 1,3,5,10- uninduced cell extracts of E. coli cells from 
4 colonies; 2,4,6,8,9- induced cell extracts of E. coli cells from 5 
colonies; 7-MWT marker 
Fig.9 Lanes 1- uninduced; 2- induced; 3- MWT marker; 4- Cell 
lysis supernatant; 5- Cell lysis pellet;6- 6M Urea solubilisation 
pellet; 7- 6M Urea solubilisation supernatant    
 
Fig.11                                                 Fig.10                                                      
 
 
 
 
      
 
 
 
Fig.10  Lane 1- load; 2- flow through; 3 to 5- washing; 6- MWT 
marker; 7- elution fraction (50 mM Imidazole); 8,9- elution 
fractions (100 mM Imidazole); 10- elution fraction (125 mM 
Imidazole) 
Fig.11  Lane 1 to 3- elution fractions (150 mM Imidazole); 4,5- 
elution fractions (175 mM Imidazole); 6- MWT marker; 7,8- 
elution fractions (200 mM Imidazole); 9,10- elution fractions (250 
mM Imidazole) 
To determine initial seed age with the highest yield 
of protein, the expression levels at 280C were 
compared between cultures at OD600 of 0.4, 0.5, 0.6, 
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0.7, 0.8, 0.9, 1.0 followed by IPTG induction, 
respectively. The results of SDS-PAGE analysis for 
whole cells indicated that the cell cultures grown at 
OD600 of about 0.6 results in the highest yield. The time 
of harvest had a less significant effect on the protein 
yield which was achieved after 3 h. Moreover, the yield 
of JIC protein was not significantly improved when 
increasing IPTG concentration from 0.5 to 1.0 mM, the 
highest yield of JIC protein was achieved at 0.5 mM/l. 
Fusion tags play a key role in the expression and 
purification of recombinant proteins. Fusion tags permit 
specific detection and purification strategies for 
proteins and enable measurements of recombinant 
protein solubilities and expressed protein quantities. 
The His-tag is most commonly used for affinity 
purification, has a small size and strong binding affinity 
to immobilized metal ion affinity chromatography 
matrices under both native and denaturing conditions. 
In this study, the nickel-affinity chromatography was 
performed with the supernatant containing protein with 
His-tag to purify. About 8 mg of highly purified protein 
was obtained from one liter of cell culture as calculated 
by determination of total protein concentration under 
this expression and purification scheme.  
 
Identification of purified protein  
To verify the identity and bioconversion activity of 
the purified recombinant protein, the enzyme was 
assayed for activity and products determined by TLC 
and HPLC. The conversion results were shown in Fig. 
12, 13, 14, and 15. A clear conversion of arteannuin b 
to artemisinin was observed by using enzyme, which 
confirms that the purified protein is the indeed. 
 
Fig.12 TLC analysis of Standard samples of AB, AN and 
methanolic extract of test sample obtained by incubating crude 
extract with AB and co-factors 
 
 
 
 
 
 
 
 
 
 
 
Fig.13 HPLC elution profile of standard Artemisinin (1.0 mg/ml) 
 
 
 
 
 
 
 
 
 
 
 
Fig.14 HPLC elution profile of Standard Arteannuin B (0.5 mg/ml) 
 
 
 
 
 
 
 
 
 
Fig.15 HPLC elution profile of test sample incubated with the 
enzyme 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Considering the fact that very low amounts of the 
enzyme are obtained in the native organism i.e. 
Streptomyces pactum, it is very important to develop a 
strategy for large-scale cost–effective production of 
such an important protein with potent bioconversion 
activity.  
In this study, the successful expression and 
purification of an enzyme involved in bioconversion of 
arteannuin B to artemisinin has been achieved. The 
enzyme was produced using pRSET A, an expression 
vector system in E. coli. Initially, the  expression was 
tested at 370C that is optimal temperature for E. coli 
and  the protein was accumulated primarily in the form 
of inclusion bodies in E. coli.  Using 8 M urea for 
denaturation followed by dialysis and refolding, the 
protein was extracted from the inclusion bodies. 
Unfortunately, this did not lead to a significant recovery 
of soluble enzyme, although some other researchers 
have reported that under such a temperature (370C) 
sufficient amounts of soluble proteins could be 
successfully purified and refolded from the inclusion 
bodies (Colleluori et al., 2005). Subsequently, we 
decreased the post-induction temperature from 370C to 
280C in shake flask culture, the production yield of 
soluble protein in E. coli was increased from 35 to 80%. 
This suggested that a lower temperature (280C) is 
beneficial for improving the expression level of soluble 
protein. Furthermore, to determine the time point when 
the highest amount of protein can be obtained, the 
expression levels at 280C were compared between the 
cultures with different optical density values. The 
experimental data showed that the time of harvest had 
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a less significant effect on the protein production, 
although the yield of soluble protein was the highest 
after 4 h of expression at 280C. In addition, proper 
optimization of induction conditions was also performed. 
The optimized conditions for protein expression in E. 
coli are a temperature of280C, a seed concentration of 
0.6OD, IPTG concentration of 0.5mMol and an 
induction time of 4hrs. 
 
Acknowledgements  
Our work described in this paper was supported 
by the Technical Educational Quality Improvement 
Program (TEQIP) for fellowship and further supports by 
the University authorities are greatly appreciated. 
 
References 
Trape JF (2001) The public health impact of 
chloroquine resistance in Africa. Am. J. Trop. Med. 
Hyg. 64 (suppl 1–2): 12–17 
Olliaro PL, Taylor WR (2003) Antimalarial compounds: 
from bench to bedside. J Exp Biol. 206(Pt 
21):3753-3759 
World Health Organization, UNICEF (2003) The Africa 
Malaria Report – 2003. 1-118.               Available 
at: 
http://www.afro.who.int/amd_2003/mainreport.pdf 
Accessed on: December 2007 
Ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna 
S (1993) Plasmodium falciparum: in vitro studies 
of the pharmacodynamic properties of drugs used 
for the treatment of severe malaria. Exp. Parasitol. 
76: 85–95 
Chen PQ, Li GQ, Guo XB, He KR, Fu YX, Fu LC, Song 
YZ (1994). The infectivity of gametocytes of 
Plasmodium falciparum from patients treated with 
artemisinin. Chin. Med. J. 107: 709–711 
Targett G, Drakeley C, Jawara M, von Seidlein L, 
Coleman R, Deen J, Pinder M, Doherty T, 
Sutherland C, Walraven G, Milligan P (2001) 
Artesunate reduces but does not prevent 
posttreatment transmission of Plasmodium 
falciparum to Anopheles gambiae. J. Infect. Dis. 
183: 1254–1259 
Christen P, Venthey JL (2001) New trends in 
extraction, identification and quantification of 
artemisinin and its derivatives. Curr. Med. Chem.  
8: 1827–1839 
Van Agtmael MA, Eggelte TA, van Boxtel CJ (1999) 
Artemisinin drugs in the treatment of malaria: from 
medicinal herb to registered medicine. Trends 
Pharmacol. Sci. 20 : 199–205 
Avery MA, Chong WKM, Jennings-white C (1992) 
Stereo selective total synthesis of (+)-artemisinin, 
the antimalarial constituent of Artemisia annua L.  
J. Am. Chem. Soc. 114: 974-979 
Laughlin JC (1994) Agricultural production of 
artemisinin- A review. Trans.Royal Soc. Trop. 
Med. Hyg. 88: (Suppl.1) 21-22 
Akhila A, Kumkum R and Thakur RS, Biosynthesis of 
artemisinic acid in Artemisia annua. 
Phytochemistry 1990, 29, 2129-2132. 
Nair MSR, Basile DV (1993) Bioconversion of 
arteannuin B to artemisinin. J. Nat. Prod. 56: 
1559-1566 
Singh A, Kaul VK, Mahajan VP, Singh A, Misra LN, 
Thakur RS, Husain A (1986) Introduction of 
Artemisia annua in India and isolation of 
artemisinin, a promising antimalarial drug. Ind. J. 
Pharmceut. Sci. 48:137-138 
Dhingra V, Pakki SR, Lakshmi Narasu M (2000b) 
Antimicrobial activity of artemisinin and its 
precursors. Curr. Sci. 78: 709-713 
Sambrook, j., & Russell, D.W. (2001). Molecular 
cloning: a laboratory manual. Cold Spring Harbor, 
NY: cold Spring Harbor Laboratory Press 
Laemmeli EK (1970) Cleavage of structural proteins 
during the assembly of the head of bacteriophage 
T4. Nat. 227: 680-685. 
Morrissey JH (1981) Silver stain for proteins in 
polyacrylamide gels: modified procedure with 
enhanced uniform sensitivity. Anal Biochem. 
117(2): 307-10 
Gupta MM, Verma RK, Gupta AP, Bhartariya KG, 
Kumar S (1997) Simultaneous determination of 
artemisinin, arteannuin B and artemisinic acid in 
Artemisia annua L. by high performance liquid 
chromatography with a combination of ODS and 
CN columns. J. Med. Arom. Pla. Sci.19: 968-972 
Colleluori, D., Tien, D., Kang, F.R., Pagliei, T., Kuss, 
R., MeCormick, T., et al. (2005). Expression, 
purification and characterization of recombinant 
cyanovirin-N for vaginal anti-HIV microbicidal 
development. Protein expression and purification, 
39,229-236. 
Xiong, C. Y., O’Keefe,B.R., Botos, I., Wlodawer, A., & 
McMahon, J. B. (2006). Overexpression and 
purification of scytovirin, a potent anti-HIV protein 
from the cultured cyanobacterium Scytonema 
varium. Protein expression and purification, 46, 
233-239.
 
  
 
